GlassScriptPhysician profile
Laura Fierke
NPI 1821472440
$3,847.57
in general payments reported to CMS, 2019-2025
32 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $103 · 2023: $225 · 2024: $1,429 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $513.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $405.39 | 2024-2025 | |
| Ucb, INC. | $364.03 | 2024-2025 | Briviact, Rystiggo, Nayzilam |
| E.R. Squibb & Sons, L.L.C. | $228.18 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $204.39 | 2024-2025 | Ultomiris |
| Biogen, INC. | $181.12 | 2024-2025 | Leqembi, Vumerity, Tysabri |
| Lilly USA, LLC | $163.27 | 2024-2025 | Kisunla, Amyvid |
| Tg Therapeutics, INC. | $161.47 | 2024-2025 | |
| Celgene Corporation | $149.10 | 2024-2025 | Zeposia |
| Emd Serono, INC. | $135.80 | 2024-2025 | Mavenclad |
| Argenx US, INC. | $130.42 | 2023-2024 | Vyvgart |
| Pfizer INC. | $114.93 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $113.90 | 2024-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $89.36 | 2024-2025 | Nuplazid |
| Lundbeck LLC | $85.38 | 2024 | Vyepti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $82.95 | 2024-2025 | |
| Mdd US Operations, LLC | $79.07 | 2024-2025 | Apokyn, Gocovri |
| Otsuka America Pharmaceutical, INC. | $78.85 | 2024-2025 | Rexulti |
| Kyowa Kirin, INC. | $72.61 | 2024 | Nourianz |
| Vanda Pharmaceuticals INC. | $69.93 | 2025 | Ponvory |
| Alnylam Pharmaceuticals INC. | $68.55 | 2025 | Onpattro |
| Axsome Therapeutics, INC. | $55.44 | 2025 | Symbravo |
| Genentech USA, INC. | $51.58 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $46.90 | 2024-2025 | |
| Mindray Ds USA, INC. | $38.75 | 2025 | Te X, Te7 Max |
| Neurelis, INC. | $36.83 | 2025 | Valtoco |
| Amgen INC. | $36.04 | 2024-2025 | Uplizna |
| Medtronic, INC. | $19.34 | 2025 | Transorb |
| Myriad Genetic Laboratories, INC. | $18.55 | 2025 | Myrisk |
| Davol INC. | $18.37 | 2025 | Ventralight St |
| Olympus America INC. | $17.88 | 2024 | Olympus |
| Grifols USA, LLC | $16.16 | 2024 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Fierke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.